Tomotherapy for prostate adenocarcinoma: A report on acute toxicity

Dose-escalated simultaneous integrated-boost treatment of prostate cancer patients via helical tomotherapy

“…The assessment of acute side effects showed low therapy related GU and GI toxicity in spite of modest dose escalation up to 76 Gy with 2.17 Gy per fraction and a permitted dose of 76 Gy to the anterior rectal wall. This is in line with other studies on dose escalation using IMRT [2,9,16,36] or hypofractionated treatment of prostate cancer [19,23,26,27,33] and studies combining hypofractionation and dose escalation applying a SIB [5,12,14], although the dose to the anterior rectal wall was limited to lower doses in several of these studies as compared to our protocol, either by excluding the rectal overlap from the boost volume or restricting the allowed doses to the overlap regions at lower dose levels.…”

Phase I–II Study of Hypofractionated Simultaneous Integrated Boost With Tomotherapy for Prostate Cancer

“…Slightly higher figures of acute G2 GU toxicity (44%) were also reported by Soete et al (24) in a Phase II multi-institutional study (56 Gy in 16 fractions) with the delivery of a substantially higher daily dose. Keiler et al (23) reported 22% Grade 2 and 4% Grade 3 in patients treated with HTT with standard fractionation. Because a large overlap between bladder/urethra and PTV is always present, a significant portion of the bladder receives the prescribed dose, whereas a good sparing of the bladder concerns the portion outside PTV.…”

“…(23), in a series of 55 patients undergoing tomotherapy treatment with standard fractionation (79.2-82 8. Gy in 44-46 fractions) reported GI acute toxicities of G1 in 64% and G2 in 25% of treated patients.…”

Helical tomotherapy for cancer treatment: a rapid health technology assessment

“…The incidence of toxicity (HT vs . similar interventions): 6 CCTs ( n = 642) were included. Acute HT toxicity (G1 (≥ G2)) was 0–25%, which was lower than that of three‐dimensional conformal radiotherapy (3D‐CRT), a linear accelerator (LINAC), traditional IMRT and C‐IGRT.…”